ZaidSAl-KadhimiMD

Hematologic Oncology

Director of the Blood and Marrow Transplantation and Cell Therapy Program (BMT) in the UAB Heersink School of Medicine’s Division of Hematology & Oncology.

Request Appointment

Overview of Dr. Al-Kadhimi

Dr. Zaid Al-Kadhimi is an oncologist in Birmingham, AL and is affiliated with University of Alabama Hospital. He received his medical degree from University of Baghdad College of Medicine and has been in practice 26 years. Dr. Al-Kadhimi accepts several types of health insurance, listed below. He is one of 73 doctors at University of Alabama Hospital who specialize in Oncology. He has more than 60 publications and over 500 citings.

Office
Emile 42nd St
2000 6th Avenue South, Floor 5
Birmingham, AL 35233
Book by Phone+1(659) 734-1799

Clinical Expertise

Hematologic oncology, Myeloproliferative disease, Stem cell transplantation, Graft-versus-host disease, Neonatal respiratory syncytial virus infection, Pain measurement, Incision site infection, Hematopoietic stem cell transplantation, Transplantation conditioning, Oropharyngeal lymphoma

Education & Training

City of Hope National Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2021
City of Hope Comprehensive Cancer CenterFellowship, Tumor Immunology research fellowship K 12 NIH award, 2002 - 2007
City of Hope National Medical CenterFellowship, Blood & Bone Marrow Transplant, 2001 - 2003
Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 1994 - 1997
University of Baghdad College of MedicineClass of 1991

Certifications & Licensure

CA State Medical License 1998 - Present
NE State Medical License 2018 - 2026
AL State Medical License 2022 - 2024
GA State Medical License 2013 - 2018
MI State Medical License 1996 - 2014
RI State Medical License 2007 - 2014
ND State Medical License 1997 - 1998
American Board of Internal Medicine Hematology

Clinical Trials

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant Start of enrollment: 2008 May 01
Completed
Phase 2
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer Start of enrollment: 2010 Mar 08
Terminated
Phase 2
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery Start of enrollment: 2010 Jul 01
Terminated
Phase 2
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT Start of enrollment: 2010 Nov 01
Completed
Phase 2
A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation Start of enrollment: 2010 Nov 01
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) Start of enrollment: 2011 Aug 17
Completed
Phase 1
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation Start of enrollment: 2020 Jan 09
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

53 citations
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease
Francisco Lopez, Pablo Parker, Auayporn Nademanee, Roberto Rodriguez, Zaid S Al-Kadhimi
Biology of Blood and Marrow Transplantation. 2005-04-01
77 citations
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transpla...
Mohamed A. Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, Mahmoud Aljurf, Taiga Nishihori
Transplantation and Cellular Therapy. 2021-08-01
39 citations
Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease
Divaya Bhutani, Gregory Dyson, Richard Manasa, Abhinav Deol, Voravit Ratanatharathorn
Biology of Blood and Marrow Transplantation. 2015-01-01

Abstracts/Posters

Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults with Acute Myeloid Leukemia (AML)
Zaid S. Al-Kadhimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Effect of Age and CD34+ Stem Cell Dose on Autologous Hematopoietic Stem Cell Transplantation Outcomes in Multiple Myeloma _ Single Institution Experience
Zaid S. Al-Kadhimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Effect of Using Multiagent Versus Single Agent Chemotherapy on Overall Survival (OS) of Older Adults with Acute Myeloid Leukemia (AML)
Zaid S. Al-Kadhimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
PriorityHealth HMO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment